A Study of PLX51107 in Advanced Malignancies

Acute Myeloid Leukemia Clinical Trial

Official title:

A Phase 1b/2a, Two-Part, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX51107 in Subjects With Advanced Hematological Malignancies and Solid Tumors

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02683395
• Other study ID #: PLX122-01
• Status: Terminated
• Phase: Phase 1
• Start date: March 2016
• Est. completion date: September 2018

Study information

• Verified date: December 2018
• Source: Plexxikon
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the investigational drug PLX51107 in subjects with advanced solid tumors (including lymphoma), and advanced hematological malignancies

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 50
• Est. completion date: September 2018
• Est. primary completion date: September 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Confirmed diagnosis of a relapsed or refractory malignancy in 1 of 2 treatment groups:

1. Group A: Subjects with any solid tumor (including lymphomas).

2. Group B: Subjects with relapsed or refractory AML, Subjects with relapsed or refractory high-risk MDS, defined as revised International Prognostic Scoring System (IPSS-R) intermediate or greater disease.

2. Age =18 years.

3. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

4. Life expectancy =3 months in the judgment of the investigator.

5. Adequate organ function.

6. Group A subjects must have measurable or evaluable disease per the appropriate disease criteria.

7. Women of child-bearing potential must have a negative serum pregnancy test at Screening and must agree to use an effective form of contraception from the time of the negative pregnancy test up to 6 months after the last dose of study drug. Effective forms of contraception include abstinence, hormonal contraceptive in conjunction with a barrier method, or a double barrier method. Women of non-child-bearing potential may be included if they are either surgically sterile or have been postmenopausal for =1 year.

8. Fertile men must agree to use an effective method of birth control during the study and for up to 6 months after the last dose of study drug.

9. All associated clinically significant toxicity from previous cancer therapy must be resolved (to =Grade 1 or baseline) prior to study treatment administration (Grade 2 alopecia is allowed).

10. Willingness and ability to provide written informed consent prior to any study-related procedures and to comply with all study requirements.

Exclusion Criteria:

1. Prior exposure to a bromodomain inhibitor, such as OTX-015 or CPI-0610.

2. Allogenic or autologous transplant for hematological malignancy with infusion of stem cells within 90 days before Cycle 1 Day 1, or on active immunosuppressive therapy for graft-versus-host disease (GVHD) or GVHD prophylaxis within 2 weeks of Cycle 1 Day 1.

3. Known uncontrolled fungal, bacterial, and/or viral infection =Grade 2.

4. Uncontrolled autoimmune hemolytic anemia or thrombocytopenia.

5. For Group A: Subjects with a history of brain metastases are ineligible. This includes previously treated brain metastases. For Group B (subjects with AML): Active symptomatic CNS involvement of AML. Subjects with previously treated leptomeningeal disease that has been effectively treated are eligible.

6. A diagnosis of acute promyelocytic leukemia (APL) or chronic myeloid leukemia (CML) in blast crisis.

7. Known or suspected allergy to the investigational agent or any agent given in association with this trial.

8. Women who are pregnant or are breast feeding.

9. Clinically significant cardiac disease

10. Inability to take oral medication or significant nausea and vomiting, malabsorption, or significant small bowel resection that, in the opinion of the Investigator, would preclude adequate absorption.

11. Subject with known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection or is known to be a carrier of hepatitis B or C.

12. Strong CYP3A4 and CYP2C8 inhibitors or inducers or CYP3A4 substrate drugs with a narrow therapeutic range taken within 14 days or 5 drug half-lives before start of study drug.

13. Active secondary malignancy

14. Major surgery or significant traumatic injury within 14 days prior to therapy

15. Receipt of anti-cancer therapy 14 days prior to Cycle 1 Day 1

16. Presence of any other medical, psychological, familial, sociological, or geographic condition potentially hampering compliance with the study protocol Subjects who are participating in any other therapeutic clinical study (observational or registry trials are allowed).

17. Subjects who have Burkitt's lymphoma or Burkitt-like lymphoma.

18. Subjects on active anticoagulation therapy including warfarin, factor Xa inhibitors, thrombin inhibitors, or heparin.

19. Subjects with documented hepatic metastases involving >50% of the hepatic parenchyma.

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Lymphoma, Non-Hodgkin
• Myelodysplastic Syndrome
• Myelodysplastic Syndromes
• Non-Hodgkin's Lymphoma
• Preleukemia
• Solid Tumors

Intervention

Drug:
• PLX51107

Locations

Country	Name	City	State
United States	MUSC/ Hollings Cancer Center	Charleston	South Carolina
United States	The Ohio State University Stephanie Spielman Comprehensive Breast Center	Columbus	Ohio
United States	Columbia University Medical Center	New York	New York
United States	Thomas Jefferson University	Philadelphia	Pennsylvania
United States	South Texas Accelerated Research Therapeutics	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Plexxikon

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of PLX51107 as measured by adverse events and serious adverse events.		1 year
Primary	Area under the concentration-time curve (AUC) of PLX51107.		1 year
Primary	Maximum observed concentration (Cmax) of PLX51107.		1 year
Primary	Time to peak concentration (Tmax) of PLX51107.		1 year
Primary	Half life (t1/2) of PLX51107.		1 year
Secondary	Overall Response Rate (ORR)	ORR is defined as the total number of patients with the best overall response according to standard criteria for the relevant malignancy divided by the total number of treated patients and expressed as a percentage.	1 year
Secondary	Duration Of Response (DOR).	DOR is defined as the time from the initial objective response to disease progression or death, whichever occurs first.	1 year
Secondary	Progression-Free Survival (PFS).	PFS time is defined as the time from the first dose of PLX51107 to disease progression or death, whichever occurs first.	1 year
Secondary	Overall Survival (OS).	OS is defined as the first dose of study drug until the date of death from any cause.	1 year